Introduction {#Sec1}
============

Every cell is inevitably exposed to extracellular and intracellular oxidative stress, every moment (Finkel [@CR19]; Ma [@CR40]). The nuclear factor erythroid 2-related factor 2 (NRF2 or NFE2L2) is a master transcription factor that activates a battery of genes which have roles in oxidative stress responses, detoxifications, and drug resistances (Bryan et al. [@CR6]; Ma [@CR41]; Mitsuishi et al. [@CR44]; Niture et al. [@CR48]). NRF2 binds to a DNA element, named antioxidant response element (ARE), in the promoter regions of its target genes to activate transcription of these genes (Nguyen et al. [@CR46]). The target genes of NRF2 includes (a) antioxidant genes such as NAD(P)H dehydrogenase \[quinone\] 1 (*NQO1*), heme oxygenase (decycling) 1 (*HMOX1*), superoxide dismutase \[Cu--Zn\] (*SOD1*), and glutamate-cysteine ligase catalytic subunit (*GCLC*); (b) detoxification genes including glutathione S-transferase A3 (*GSTA3*) and thioredoxin reductase 1, cytoplasmic (*TXNRD1*); (c) and drug resistance genes such as ATP-binding cassette sub-family G member 2 (*ABCG2*) and ATP-binding cassette, sub-family C (CFTR/MRP), member 5 (*ABCC5*) (Malhotra et al. [@CR43]; Nguyen et al. [@CR46]).

Reactive oxygen species (ROS), which are produced by various exogenous or endogenous sources, are double-edge swords. Under tight cellular control, ROS act as important signaling molecules to regulate diverse cellular functions including transcriptional regulation and signal transduction (Corcoran and Cotter [@CR13]; Finkel [@CR19]; Jennings et al. [@CR27]; Ma [@CR40]; Ray et al. [@CR52]). On the contrary uncontrolled production of ROS causes various human diseases through DNA damage and impaired cellular functions via oxidative stress (Acharya et al. [@CR1]; Caputo et al. [@CR9]; Kakehashi et al. [@CR30]; Kryston et al. [@CR35]; Saeidnia and Abdollahi [@CR53]; Storr et al. [@CR59]). As an ROS sensor, the level of NRF2 is tightly regulated by a set of proteins through proteasome-dependent proteloysis. The well-known negative regulator of NRF2 is the Kelch-like erythroid cell-derived protein with CNC homology-associated protein 1 (KEAP1). KEAP1 binds and destabilized NRF2 through ubiquitin-dependent proteasomal degradation under normal reducing condition (Bryan et al. [@CR6]; Mitsuishi et al. [@CR44]; Niture et al. [@CR48]; Storr et al. [@CR59]). NRF2 stability is also regulated by the CR6-interacting factor 1 (CRIF1) under both reducing and oxidative stress conditions (Kang et al. [@CR31]) and the glycogen synthase kinase 3β (GSK3β)/β-transducin repeat-containing protein (β-TrCP) axis (Chowdhry et al. [@CR12]; Rada et al. [@CR50]; Rada et al. [@CR51]). It has been reported that stability of NRF2 is also regulated by competitive protein--protein interaction to inhibit NRF2-KEAP1 binding by various proteins such as p21 (Chen et al. [@CR11]), the Wilms tumor gene on X chromosome (WTX) (Camp et al. [@CR7]), p62 (Komatsu et al. [@CR34]), the partner and localizer of BRCA2 (PALB2) (Ma et al. [@CR42]), the dipeptidyl peptidase III (DPP3) (Hast et al. [@CR21]), and the breast cancer susceptibility gene 1 (BRCA1) (Gorrini et al. [@CR20]).

NRF2 functions as either a protector against tumorigenesis or oncogene (DeNicola et al. [@CR15]; Kensler and Wakabayashi [@CR33]; Loboda et al. [@CR38]; Muller and Hengstermann [@CR45]). Stability and activity of NRF2 is important in human diseases, especially in cancers. While NRF2 decreases tumor susceptibility in most carcinogenesis models, constitutive activation of NRF2 may enhance tumor cell proliferation and/or confer drug resistance in lung, pancreatic as well as colorectal cancer cells (Arlt et al. [@CR4]; Bryan et al. [@CR6]; Duong et al. [@CR17]; Homma et al. [@CR23]; Hong et al. [@CR24]; Lister et al. [@CR37]; Mitsuishi et al. [@CR44]; Niture et al. [@CR48]; Singh et al. [@CR57]; Storr et al. [@CR59]; Yamadori et al. [@CR63]). Indeed, NRF2 is up-regulated in many types of tumors through somatic mutations that block KEAP1-dependent regulation of NRF2 stability (Mitsuishi et al. [@CR44]; Niture et al. [@CR48]; Storr et al. [@CR59]). Targeting NRF2 either by RNA interference or by small molecules inhibited tumor growth and increased efficacy of chemotherapy (Singh et al. [@CR57]) or EGF-driven proliferation (Yamadori et al. [@CR63]) in non-small cell lung cancer models and reduced the proliferation and drug-resistance in human lung cancer cells (Homma et al. [@CR23]) or human pancreatic cancer cells (Arlt et al. [@CR4]; Duong et al. [@CR17]; Hong et al. [@CR24]; Lister et al. [@CR37]). Additionally in primary murine cell models, oncogenes including K-Ras, B-Raf, and Myc increased the transcription of *Nrf2* gene to activate antioxidant and detoxification program preferable for oncogenesis (Kang et al. [@CR32]). Under these conditions, genetic targeting of K-Ras^G12D^-driven Nrf2 impaired in vivo tumorigenesis (Kang et al. [@CR32]). Taken together, genome-wide analysis of NRF2-responsive genes in specific cancer types will give insights on the context-dependent roles of NRF2. In this work we delineated NRF2-responsive genes in As-PC1 pancreatic cancer cell lines established from metastatic cancer cell in ascites fluid (Chen et al. [@CR10]).

Materials and methods {#Sec2}
=====================

Cell culture and reagents {#Sec3}
-------------------------

AsPC-1 cells were obtained from the Korean Cell Line Bank (Seoul, Korea) and maintained in RPMI-1640 media (HyClone, Logan, UT) supplemented with 20 % FBS (Invitrogen, Carlsbad, CA) and 100 U/ml penicillin/streptomycin (Welgene, Daegu, Korea). The cells were cultured in a humidified 5 % CO~2~ incubator at 37 °C. The cell viability and cell counting were assessed by the Luna Automated Cell Counter (Logos Biosystems, Gyunggi-do, Korea). Tert-butylhydroquinone (tBHQ) was purchased from Sigma (St. Louis, MO) and stored at −20 °C dissolved in DMSO with small aliquots.

siRNA transfection {#Sec4}
------------------

For *NRF2* knockdown, exponentially proliferating cells were transfected with synthesized control siRNA (5′-gacgagcggcacgugcacauu-3′) or *NRF2* specific siRNA (5′-gaguaugagcuggaaaaacuu-3′) (Hong et al. [@CR24]), both purchased from Bioneer (Daejeon, Korea) using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol.

Cell cycle analysis {#Sec5}
-------------------

Cell cycle analysis was carried out by propidium iodide staining and laser detection of FL2 signal using FACSCalibur (BD Science, Franklin Lakes, NJ), and the data were analyzed by CellQuest Pro software (BD Science). After treatment (72 h for siRNA and 16 h for tBHQ treatment respectively), cells were washed with PBS, fixed 70 % ethanol, and stained with propidium iodide solution (20 μg/ml) containing RNaseA (100 μg/ml) after removal of ethanol.

RNA extraction {#Sec6}
--------------

Total RNA from AsPC-1 cell lines were prepared with the RNeasy Mini kit (Qiagen, Valencia, CA) according to the manufacturer's protocols. The purity and integrity of RNA sample was evaluated by determining the OD260/230 ratio, 28S/18S ratio, peak pattern and electrophoretic migration patterns on Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA).

Western blot analysis {#Sec7}
---------------------

After 72 h of siRNA treatment or 16 h of tBHQ treatment, AsPC-1 cells were lysed in 10 mM Tris--HCl (pH 7.0), 100 mM NaCl, 1 % triton X-100, 1 mM DTT, 20 μg/ml aprotinin, 2.5 μg/ml leupeptin, and 0.5 mM PMSF. Lysates were resolved on 10 % sodium dodecyl sulfate--polyacrylamide by gel electrophoresis (SDS-PAGE) and transferred onto 0.45 μm pore size Polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA), and immunoblotted with following antibodies: Cyclin B1 antibody (CST\#4135, Cell Signaling Technology, Danvers, MA), Cyclin D1 (CST \#2922, Cell Signaling Technology), NRF2 (sc-103032, Santa Cruz Biotechnology, Santa Cruz, CA), Erk-1 (sc-94, Santa Cruz Biotechnology), Cyclin A (sc-239, Santa Cruz Biotechnology). Horseradish peroxidase (HRP)-conjugated goat anti-rabbit (sc-2004, Santa Cruz Biotechnology) or anti-mouse antibodies (sc-2005, Santa Cruz Biotechnology) were used as secondary antibodies.

cDNA microarray analysis {#Sec8}
------------------------

The cDNA microarray analysis was carried out with fluorescence labeling of cRNA and hybridization using 4 × 44 K Human whole genome microarray (Agilent technologies, Palo Alto, CA) for tBHQ treated cells. For cDNA microarray analysis of NRF2 siRNA treated cell, Ilumina Biochip system (HT-12) was used. For each microarray three RNA samples of independent experiment were used.

Statistical analysis {#Sec9}
--------------------

Data were analyzed by either Student's *t* test (tBHQ treated sample) or LPE test (siRNA treated sample) (Jain et al. [@CR26]) and the results have been expressed *p* values and mean values.

Results and discussion {#Sec10}
======================

The AsPC-1 pancreatic cancer cell line, used in this work had been established from metastatic abdominal ascites fluid cells originated from metastatic pancreatic cancer (Chen et al. [@CR10]). It contains well known mutations of pancreatic cancer including, KRAS (p.G12D), TP53 (p.C135fsP35), SMAD4 (p.R100T), and other mutations common in cancers as well: COL2A1 (c.915 + 3A \> G), FBXW7 (p.R465C), HEY1 (p.I178V), KIF5B (p.Q467K), MLL (p.P3536H), RNF43 (p.S720\*) (Deer et al. [@CR14]). The relative expression level of NRF2 between various pancreatic cancer cell lines including immortalized human pancreatic ductal epithelial cell lines (HPDE) using GEO2R analysis with pre-deposited microarray data (Thu et al. [@CR62]) at NCBI Gene Expression Ominbus (<http://www.ncbi.nlm.nih.gov/geo/geo2r/?acc=GSE40099&platform=GPL6480>) is presented in supplementary Fig. [1](#Fig1){ref-type="fig"}. NRF2 was reported to be increased in pancreatic cancer cell lines and the nuclear level of NRF2 in AsPC-1 cell line has been reported to be relatively higher than in immortalized pancreatic ductal epithelial cells (Hong et al. [@CR24]; Lister et al. [@CR37]).Fig. 1Cell cycle analysis of NRF2 siRNA-treated or tBHQ-treated AsPC-1 cell line. **a** A representative image of FL2 histogram of FACS analysis. The figure in the *lower right quadrant* is combined FACS analysis images with notion of 2 and 4 N nuclear ploidy. **b** Immunoblot anaylysis of tBHQ-treated (100 μM 16 h) or siRNA-treated samples (72 h). AsPC-1 cells were seeded in 6-well plates and treated with tBHQ (or DMSO) or NRF2 siRNA (or control siRNA). Cells were harvested and whole cell lysates were prepared, electrophoresed and transferred onto PVDF membranes. Immunoblotting was performed with indicated antibodies and Erk-1 was used as loading control

An antioxidant tBHQ increases the level of NRF2 protein by stabilization and stimulates the expression of oxidative stress metabolizing genes (Hirose et al. [@CR22]; Li et al. [@CR36]). Prior to cDNA microarray we tested whether tBHQ or NRF2 siRNA treatment can change the cell cycle of AsPC-1 cell line. As shown in Fig. [1](#Fig1){ref-type="fig"}a no apparent change in cell cycle distribution was observed along with no accumulation of sub G1 population. Immunoblot analysis also revealed that no apparent change of cell cycle marker proteins including cyclin B1 and cyclin D. The level of NRF2 protein was shown to be increased in tBHQ treated cells and decreased in NRF2 siRNA treated sample (Fig. [1](#Fig1){ref-type="fig"}b).

To identify changed genes upon treatment of 100 μM tBHQ, we used the Agilent 44 k whole genome cDNA array chip. We also used the Ilumina HT-12 whole genome cDNA array chip for NRF2 siRNA mediated gene expression analysis. Three independent RNA samples were used in these experiments. After removal of marginal or absent signal spots, 20,312 positive spots were obtained from tBHQ-treated sample and 16,423 positive spots were obtained from NRF2 siRNA-treated sample. Hierarchical cluster image of NRF2 siRNA treatment samples reveals that the gene expression pattern of three siRNA-treated sample and three control siRNA-treated samples are adequately clustered (Fig. [2](#Fig2){ref-type="fig"}a). Figure [2](#Fig2){ref-type="fig"}b shows the hierarchical cluster image of cDNA microarray of tBHQ-treated sample indicating three independent samples share concordant RNA expression pattern.Fig. 2Hierarchical cluster image of the gene expression profiles of cDNA microarray analysis. **a** cDNA array of NRF2 siRNA-treated (2TRE, 3 TRE, 4 TRE) and control siRNA-treated sample (2 Con, 3 Con, 4 Con). Each mRNA sample was labeled and hybridized with cDNA array chip (HT 12, Ilumina) and cluster analysis was carried out. **b** cDNA array of tBHQ-treated versus DMSO-treated AsPC-1 cells. Two sets of mRNA (tBHQ vs DMSO) with triplicate samples were labeled differently and hybridized. The *red color* indicated up-regulated genes and the *green color* indicates down-regulated genes

Further statistic tests after normalization of positive spots provide statistically significant 533 array sets from tBHQ-treated samples (supplementary Table 1) and 189 array sets from NRF2 siRNA-treated samples (supplementary Table 2). Table [1](#Tab1){ref-type="table"} shows a list of genes which show more than two fold increase of expression (p \< 0.05) after treatment of tBHQ (57 genes). Among them *AKR1B10*, *FCER1G*, *AKR1B1*, *AKR1B15*, *AADAC*, *GRK5*, *HDAC9*, *AKR1C1*, *CYP4F3*, *CYP4F2*, *ALDH3A1*, *FANCD2*, *TXNRD1* and *SLC7A11* are classified as members of drug response genes or oxidative stress response genes according to gene ontology (Table [1](#Tab1){ref-type="table"}). The lists of genes decreased by tBHQ treatment are listed in Table [2](#Tab2){ref-type="table"}. Four genes classified as drug response or oxidative stress response genes were identified: *PDE7A*, *TGM1*, *CYTH1* and *EPS15*. The list of top 50 genes which were decreased by NRF2 siRNA treatment are presented in Table [3](#Tab3){ref-type="table"}. The listing is arbitrary but these genes showed more than 40 % reduction in expression. The siRNA mediated knockdown of *NRF2* significantly reduced the expression of oxidative stress or drug response genes including, *AKR1B10*, *ALDH1A1*, *HGD*, *TFF1*, *GPX2*, *ALDH3A1*, *PPP1R1B*, *AKR1C4*, *ABCB6*, *ABCC3*, *NFE2L2*, *EPHX1*, *ASGR1*, *SLC2A5*, *LGALS1* and *MTR* (Table [3](#Tab3){ref-type="table"}). The expression of *NRF2* itself was significantly (p \< 0.001, 50 % reduction) decreased by the treatment of siRNA reflecting the reliable quality control of siRNA treatment. On the contrary to NRF2 siRNA treatment the change of *NRF2* expression by the tBHQ treatment was not significant (data not shown) since tBHQ stabilized NRF2 protein but had no effect on the mRNA level of NRF2. The array results of increased genes under the NRF2 activated status (tBHQ treatment) and decreased genes by the NRF2 siRNA treatment seem to be coincide. We listed top 50 gene records with increased expression upon NRF2 siRNA treatment in Table [4](#Tab4){ref-type="table"}. Ten genes classified as drug response or oxidative stress response genes were identified as increasing genes in NRF2 siRNA treatment: *CD36, ALPP, HLA*-*B, TGM2, FABP3, CTSH, CYR61, TIMP2, PRNP* and *NR4A2*. We also analyzed metastasis related genes in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}.Table 1List of genes with (57 records) with more than two fold increase (p \< 0.05) in tBHQ-treated AsPC-1 cellsProbe ID (Agilent 44 k)Gene symbolFold changep ValueGene nameA_23_P415015ATL210.5285.52E−04Atlastin GTPase 2A_33_P3416588RIT210.3416.05E−04Ras-like without CAAX 2A_23_P83134**GAS1** ^**M**^4.7521.13E−03Growth arrest-specific 1A_33_P3257155SMAP14.6974.41E−05Small ArfGAP 1A_24_P129341**AKR1B10** ^**D,\ O**^4.6948.83E−04Aldo--keto reductase family 1, member B10A_23_P93641**AKR1B10** ^**D,\ O**^4.6528.91E−04Aldo--keto reductase family 1, member B10A_33_P3272628**FCER1G** ^**D**^4.6211.31E−04Fc fragment of IgE, high affinity I, receptor for; gamma polypeptideA_23_P258190**AKR1B1** ^**D,\ O**^4.5889.03E−04Aldo--keto reductase family 1, member B1A_23_P80570**AADAC** ^**D**^4.4889.31E−04Arylacetamide deacetylase (esterase)A_33_P3244640**GRK5** ^**D,\ M**^4.4331.06E−03G protein-coupled receptor kinase 5A_33_P3380992**AKR1B15** ^**D**^4.4159.39E−04Aldo--keto reductase family 1, member B15A_33_P3304688TNAP4.2721.06E−03TRAFs and NIK-associated proteinA_23_P404162**HDAC9** ^**D,\ O,\ M**^4.1761.07E−03Histone deacetylase 9A_33_P3254751LOC1001313553.7031.67E−03Hypothetical protein LOC100131355A_33_P3265394WDR743.0712.51E−03WD repeat domain 74A_23_P257971**AKR1C1** ^**D,\ O,\ M**^3.0051.59E−03Aldo--keto reductase family 1, member C1A_23_P323143ZNF7672.9191.76E−04Zinc finger family member 767A_33_P3350853LOC2027812.8851.74E−04Hypothetical LOC202781A_23_P96623OPN1MW2.8792.65E−03Opsin 1 (cone pigments), medium-wave-sensitiveA_33_P3396956C1orf1722.8741.87E−03Chromosome 1 open reading frame 172A_23_P67453TNNI32.8462.95E−04Troponin I type 3 (cardiac)A_23_P46238CELA2A2.8232.08E−03Chymotrypsin-like elastase family, member 2AA_24_P943949LRRC8B2.7753.48E−03Leucine rich repeat containing 8 family, member BA_23_P125042ZNF2222.7633.62E−03Zinc finger protein 222A_33_P3268234KRT392.6923.44E−03Keratin 39A_32_P180741TNK22.6903.52E−03Tyrosine kinase, non-receptor, 2A_24_P68908LOC3448872.6002.11E−03Similar to hCG2041270A_33_P3314401CLDN162.5803.96E−03Claudin 16A_33_P3365117**AKR1C1** ^**D,\ O,\ M**^2.5634.45E−03Aldo--keto reductase family 1, member C1A_24_P152968**AKR1C1** ^**D,\ O,\ M**^2.5622.18E−03Aldo--keto reductase family 1, member C1A_23_P63432RHBDL22.5092.89E−03Rhomboid, veinlet-like 2 (Drosophila)A_33_P3294277**CYP4F3** ^**D**^2.4892.59E−03Cytochrome P450, family 4, subfamily F, polypeptide 3A_23_P28697HAAO2.3944.38E−033-hydroxyanthranilate 3,4-dioxygenaseA_24_P678418DICER1-AS2.3782.74E−03Hypothetical locus FLJ45244A_23_P46222TRIM462.3702.85E−03Tripartite motif containing 46A_33_P3389363C19orf542.3643.17E−03Chromosome 19 open reading frame 54A_23_P502047CHRD2.3453.99E−03ChordinA_23_P50710**CYP4F2** ^**D**^2.3404.52E−03Cytochrome P450, family 4, subfamily F, polypeptide 2A_33_P3315239ZNF72.3374.01E−03Zinc finger protein 7A_33_P3336287SEC61A22.3224.20E−03Sec61 alpha 2 subunit (S. cerevisiae)A_23_P301521KIAA14622.2756.97E−03KIAA1462A_33_P3420900PATE22.2721.54E−03Prostate and testis expressed 2A_23_P218793XPNPEP32.1873.38E−03X-prolyl aminopeptidase (aminopeptidase P) 3, putativeA_33_P3265714C2orf612.1841.05E−02Chromosome 2 open reading frame 61A_33_P3252381PCA32.1671.36E−03Prostate cancer antigen 3 (non-protein coding)A_33_P3378915ARHGEF182.1643.58E−03Rho/Rac guanine nucleotide exchange factor (GEF) 18A_33_P3397520KRTAP10-122.1374.86E−03Keratin associated protein 10-12A_24_P307135TNXB2.1117.60E−03Tenascin XBA_33_P3259548WDR5B2.0974.74E−03WD repeat domain 5BA_23_P38190ORMDL32.0844.14E−03ORM1-like 3 (S. cerevisiae)A_23_P3956C1QTNF12.0693.97E−03C1q and tumor necrosis factor related protein 1A_33_P3238433**ALDH3A1** ^**D,\ O**^2.0633.96E−03Aldehyde dehydrogenase 3 family, memberA1A_23_P345678**FANCD2** ^**D,\ O,\ M**^2.0465.27E−03Fanconi anemia, complementation group D2A_33_P3351120**TXNRD1** ^**D,O**^2.0424.10E−03Thioredoxin reductase 1A_33_P3258581LOC3897912.0325.19E−03Hypothetical LOC389791A_33_P3242623**SLC7A11** ^**D,\ M**^2.0114.31E−03Solute carrier family 7, member 11A_24_P223163NAF12.0064.47E−03Nuclear assembly factor 1 homolog (S. cerevisiae)The fold increased/decreased values are mean of three independent samples. Superscripts were assigned to drug response genes (D), oxidative stress response genes (O) and metastasis (M) related genes according to gene ontology. These gene symbols are presented in bold styleTable 2Top 50 gene records with decreased expression (p \< 0.05) in tBHQ-treated AsPC-1 cellsProbe ID (Agilent 44 k)SymbolFold changep ValueGene nameA_23_P337849CELF30.3981.10E−02CUGBP, Elav-like family member 3A_24_P322229RASL10B0.4667.41E−03RAS-like, family 10, member BA_33_P3213512COQ50.4681.24E−02Coenzyme Q5 homolog, methyltransferase (S. cerevisiae)A_23_P60627**ALOX15B** ^**M**^0.4751.30E−02Arachidonate 15-lipoxygenase, type BA_33_P3356004UCKL1-AS10.5423.18E−02UCKL1 antisense RNA 1 (non-protein coding)A_33_P3247678LOC1001308760.5507.40E−03Uncharacterized LOC100130876A_33_P3245679LOC1001299400.5542.98E−02Uncharacterized LOC100129940A_23_P146325ASAP1-IT10.5669.59E−03ASAP1 intronic Transcript 1 (non-protein coding)A_32_P110016LOC7278690.5673.94E−02Uncharacterized LOC727869A_23_P59988SLC35G50.5672.72E−02Solute carrier family 35, member G5A_33_P3281363TRIP120.5731.24E−02Thyroid hormone receptor interactor 12A_23_P114445MAGEE10.5771.23E−02Melanoma antigen family E, 1A_24_P360529**PDE7A** ^**D**^0.5893.23E−02Phosphodiesterase 7AA_23_P18055C3orf510.5971.85E−02Chromosome 3 open reading frame 51A_33_P3544880LOC1429370.6221.05E−02Uncharacterized protein BC008131A_33_P3576797LOC1588630.6221.17E−02Uncharacterized LOC158863A_24_P314597KIAA0319L0.6311.73E−02KIAA0319-likeA_33_P3272399LOC6454270.6322.14E−02Uncharacterized LOC645427A_33_P3256500ATXN20.6362.07E−02Ataxin 2A_33_P3248265LTB0.6472.48E−02Lymphotoxin beta (TNF superfamily, member 3)A_33_P3522511KIAA04850.6493.41E−02Uncharacterized LOC57235A_33_P3319134LOC1005061910.6493.60E−02Uncharacterized protein LOC100506191A_24_P693321LOC1001909860.6496.81E−03Uncharacterized LOC100190986A_23_P65618**TGM1** ^**D**^0.6532.67E−02Transglutaminase 1A_33_P3249259TGM60.6561.57E−02Transglutaminase 6A_23_P108932RPL23AP320.6584.13E−02Ribosomal protein L23a pseudogene 32A_33_P3333777LOC1001293870.6613.27E−02Uncharacterized LOC100129387A_23_P326142C7orf540.6633.05E−02Chromosome 7 open reading frame 54A_33_P3335840WDR330.6663.53E−02WD repeat domain 33A_33_P3324137PRO06280.6681.90E−02Uncharacterized LOC29053A_33_P3393010PKDCC0.6692.08E−02Protein kinase domain containing, cytoplasmic homolog (mouse)A_33_P3321372CNTNAP30.6731.20E−02Contactin associated protein-like 3A_33_P3250018HCFC20.6734.56E−02Host cell factor C2A_33_P3762913LOC1002165460.6773.29E−02uncharacterized LOC100216546A_33_P3223990TPM30.6803.66E−02Tropomyosin 3A_33_P3503937LOC2845810.6831.31E−02Uncharacterized LOC284581A_33_P3357382POGZ0.6851.94E−02Pogo transposable element with ZNF domainA_33_P3276913TTC30.6853.02E−02Tetratricopeptide repeat domain 3A_33_P3363091VAC140.6852.87E−02Vac14 homolog (S. cerevisiae)A_33_P3356525FLJ454820.6861.22E−02Uncharacterized LOC645566A_33_P3310751LOC1001322490.6904.21E−02Uncharacterized LOC100132249A_33_P3345743PFN1P20.6912.36E−02Profilin 1 pseudogene 2A_23_P6561EBLN20.6921.29E−02Endogenous Bornavirus-like nucleoprotein 2A_23_P59613**FZD9** ^**M**^0.6921.63E−02Frizzled family receptor 9A_33_P3397795C14orf1350.6941.31E−02Chromosome 14 open reading frame 135A_33_P3304533RNF2070.6962.21E−02Ring finger protein 207A_33_P3380405**CYTH1** ^**D**^0.6991.98E−02Cytohesin 1A_33_P3538279PRO28520.6992.61E−02Uncharacterized protein PRO2852A_23_P60793ASMTL-AS10.7033.95E−02ASMTL antisense RNA 1 (non-protein coding)A_33_P3371752**EPS15** ^**D,\ M**^0.7041.52E−02Epidermal growth factor receptor pathway substrate 15A_33_P3355371TTC9C0.7043.17E−02Tetratricopeptide repeat domain 9CThe fold increased/decreased values are mean of three independent samples. Superscripts were assigned to drug response genes (D), oxidative stress response genes (O) and metastasis (M) related genes according to gene ontology. These gene symbols are presented in bold styleTable 3Top 50 gene records with decreased expression (p \< 0.05) in NRF2 siRNA-treated AsPC-1 cellsProbe IDIluminaSymbolFold changep Value (LPE t-test)Gene nameILMN_1672148**AKR1B10** ^**D,\ O**^0.2410.00E+00Aldo--keto reductase family 1, member B10 (aldose reductase)\*ILMN_1709348**ALDH1A1** ^**D,\ O,\ M**^0.2530.00E+00Aldehyde dehydrogenase 1 family, member A1ILMN_2096372**ALDH1A1** ^**D,\ O,\ M**^0.3584.86E−12Aldehyde dehydrogenase 1 family, member A1ILMN_2198239**HGD** ^**O**^0.3935.28E−08Homogentisate 1,2-dioxygenase (homogentisate oxidase)ILMN_1794829C6orf1170.4101.82E−07Chromosome 6 open reading frame 117ILMN_1729117COL5A20.4181.54E−08Collagen, type V, alpha 2ILMN_1811387**TFF3** ^**M**^0.4260.00E+00Trefoil factor 3 (intestinal)ILMN_1781745C9orf1520.4451.43E−06Chromosome 9 open reading frame 152ILMN_1722489**TFF1** ^**D,\ O,\ M**^0.4451.24E−10Trefoil factor 1ILMN_1800091RARRES10.4651.40E−06Retinoic acid receptor responder (tazarotene induced) 1ILMN_2133205**GPX2** ^**D,\ O**^0.4693.59E−10Glutathione peroxidase 2 (gastrointestinal)ILMN_1702503**ALDH3A1** ^**D,\ O**^0.4813.84E−06Aldehyde dehydrogenase 3 family, memberA1\*ILMN_2412336AKR1C20.4883.94E−05Aldo--keto reductase family 1, member C2ILMN_2304495**PPP1R1B** ^**D,\ O**^0.4891.57E−05Protein phosphatase 1, regulatory (inhibitor) subunit 1BILMN_1684873ARSD0.4915.26E−05Arylsulfatase DILMN_1772951ST6GALNAC10.4921.06E−07ST6 (α-N-acetyl-neuraminyl-2,3-β-galactosyl-1, 3)-N-acetylgalactosaminide α-2,6-sialyltransferase 1ILMN_1687757**AKR1C4** ^**O**^0.5061.81E−04Aldo--keto reductase family 1, member C4ILMN_2193980**ABCB6** ^**D**^0.5095.44E−06ATP-binding cassette, sub-family B (MDR/TAP), member 6ILMN_2161330**SPDEF** ^**M**^0.5132.61E−03SAM pointed domain containing ets transcription factorILMN_1677814**ABCC3** ^**D,\ O**^0.5183.96E−06ATP-binding cassette, sub-family C (CFTR/MRP), member 3ILMN_1790909**NFE2L2** ^**D,\ O**^0.5196.27E−04Nuclear factor (erythroid-derived 2)-like 2ILMN_1680652SELENBP10.5203.74E−04Selenium binding protein 1ILMN_1756685DEPDC60.5236.27E−04DEP domain containing 6ILMN_1704353IGSF30.5256.27E−04Immunoglobulin superfamily, member 3ILMN_1743620RARRES10.5281.47E−03Retinoic acid receptor responder (tazarotene induced) 1ILMN_1752932MPZL20.5322.94E−03Myelin protein zero-like 2ILMN_1701025**EPHX1** ^**D,\ O**^0.5354.13E−05Epoxide hydrolase 1, microsomal (xenobiotic)ILMN_1680738C5orf130.5436.93E−03Chromosome 5 open reading frame 13ILMN_1653956LOC6446240.5456.70E−03PREDICTED: hypothetical LOC6446241ILMN_1769013**ASGR1** ^**D,\ O**^0.5452.13E−04Asialoglycoprotein receptor 1ILMN_1748352**CTSL2** ^**M**^0.5473.16E−03Cathepsin L2ILMN_1659984MEP1A0.5503.94E−05Meprin A, alpha (PABA peptide hydrolase)ILMN_1736042ME10.5512.91E−03Malic enzyme 1, NADP(+)-dependent, cytosolicILMN_1779015ZNF4670.5541.05E−03Zinc finger protein 467ILMN_1761247**PIR** ^**M**^0.5611.83E−02Pirin (iron-binding nuclear protein)ILMN_2255579RAB370.5656.27E−04RAB37, member RAS oncogene familyILMN_1726114SLC45A30.5661.96E−06Solute carrier family 45, member 3ILMN_1671337**SLC2A5** ^**D,\ O**^0.5666.19E−03Solute carrier family 2 (facilitated glc/fruc transporter), member 5ILMN_2278335LOC4412820.5674.28E−04Similar to aldo--keto reductase family 1, member B10ILMN_1712305CYBRD10.5726.27E−04Cytochrome b reductase 1ILMN_2383383**PIR** ^**M**^0.5761.74E−02Pirin (iron-binding nuclear protein)ILMN_1657547CCDC340.5782.33E−04Coiled-coil domain containing 34ILMN_1678692MPRIP0.5799.67E−03Myosin phosphatase Rho interacting proteinILMN_1723978**LGALS1** ^**D,\ O,\ M**^0.5795.76E−03Lectin, galactoside-binding, soluble, 1ILMN_2087692CYBRD10.5811.45E−03Cytochrome b reductase 1ILMN_1802100ADAM280.5873.29E−02ADAM metallopeptidase domain 28ILMN_1761733HLA-DMB0.5877.93E−03Major histocompatibility complex, class II, DM betaILMN_1695397LOC6441510.5881.64E−03PREDICTED: similar to calpain 8 (LOC644151)ILMN_1670801**MTR** ^**D,\ O**^0.5913.80E−025-methyltetrahydrofolate-homocysteine methyltransferaseILMN_1699728BTD0.5911.74E−02Homo sapiens biotinidaseThe fold changes are mean of three independent samples. Superscripts were assigned to drug response genes (D), oxidative stress response genes (O) and metastasis (M) related genes according to gene ontology. These gene symbols are presented in bold styleTable 4Top 50 gene records with increased expression (p \< 0.05) in NRF2 siRNA-treated AsPC-1 cellsProbe ID IluminaSymbolFold changep Value (LPE t-test)Gene nameILMN_1796094**CD36** ^**D,\ O,\ M**^4.4764.78E−25CD36 molecule (thrombospondin receptor)ILMN_1784863**CD36** ^**D,\ O,\ M**^3.4164.13E−13CD36 molecule (thrombospondin receptor)ILMN_1656501DUSP52.6641.24E−08Dual specificity phosphatase 5ILMN_1679262**DPYSL3** ^**M**^2.3897.67E−11Dihydropyrimidinase-like 3ILMN_1693789**ALPP** ^**D,\ O**^2.2961.82E−07Alkaline phosphatase, placental (Regan isozyme)ILMN_1700144ITGA102.2417.76E−06Integrin, alpha 10ILMN_1787691CITED42.1575.80E−06Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4ILMN_2108735EEF1A22.0946.43E−03Eukaryotic translation elongation factor 1 alpha 2ILMN_1813386CORO62.0734.73E−05Coronin 6ILMN_2368530**IL32** ^**M**^2.0421.06E−07Interleukin 32ILMN_1776861HAP12.0392.25E−04Huntingtin-associated protein 1ILMN_2317581SHANK32.0232.48E−05SH3 and multiple ankyrin repeat domains 3ILMN_2317580SHANK31.9501.28E−03SH3 and multiple ankyrin repeat domains 3ILMN_2049417TMEM86B1.9208.22E−04Transmembrane protein 86BILMN_1778010**IL32** ^**M**^1.9192.26E−04Interleukin 32ILMN_1697460REEP61.9154.15E−03Receptor accessory protein 6ILMN_1710553TMEM151A1.9002.61E−03Transmembrane protein 151AILMN_1678086CCDC74A1.8942.68E−03Coiled-coil domain containing 74AILMN_1778401**HLA-B** ^**D,\ O,\ M**^1.8788.82E−05Major histocompatibility complex, class I, BILMN_1709659TMEM151A1.8681.74E−02Transmembrane protein 151AILMN_1734707CHST131.8573.42E−03Carbohydrate (chondroitin 4) sulfotransferase 13ILMN_1794501**HAS3** ^**M**^1.8401.28E−03Hyaluronan synthase 3ILMN_1674580TRIM361.8341.67E−03Tripartite motif-containing 36ILMN_1761912MGAT11.8241.29E−02Mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyl transferaseILMN_1679267**TGM2** ^**D,\ O,\ M**^1.8181.28E−03Transglutaminase 2ILMN_2136971**FABP3** ^**D,\ O,\ M**^1.8155.45E−03Fatty acid binding protein 3, muscle and heartILMN_2077680CLDND21.8142.15E−03Claudin domain containing 2ILMN_1669362IGFBP61.8113.15E−06Insulin-like growth factor binding protein 6ILMN_2361737TRIM361.8092.94E−03Tripartite motif-containing 36ILMN_1805842FHL11.7961.82E−03Four and a half LIM domains 1ILMN_2390853**CTSH** ^**D,\ O**^1.7802.68E−03Cathepsin HILMN_1676712LOC6455531.7781.28E−03PREDICTED: hypothetical LOC645553ILMN_2171384**CXCL5** ^**M**^1.7661.17E−02Chemokine (C-X-C motif) ligand 5ILMN_1780057RENBP1.7646.43E−03Renin binding proteinILMN_2188264**CYR61** ^**O,\ M**^1.7595.85E−03Cysteine-rich, angiogenic inducer, 61ILMN_1782305**NR4A2** ^**O,\ M**^1.7449.73E−03Nuclear receptor subfamily 4, group A, member 2ILMN_1792538CD71.7403.63E−02CD7 moleculeILMN_1705814KRT801.7389.51E−03Keratin 80ILMN_1721876**TIMP2** ^**O,\ M**^1.7333.53E−02TIMP metallopeptidase inhibitor 2ILMN_1655915**MMP11** ^**M**^1.7252.02E−02Matrix metallopeptidase 11 (stromelysin 3)ILMN_1656361LOC2011751.7221.43E−02Hypothetical protein LOC201175ILMN_1785646PMP221.7204.71E−02Peripheral myelin protein 22ILMN_1748844CNKSR31.7131.29E−02CNKSR family member 3ILMN_2360415**PRNP** ^**O**^1.7132.15E−02Prion protein (PRNP)2ILMN_1814296TRPM61.7112.15E−03Transient receptor potential cation channel, subfamily M, member 6ILMN_1667295VASN1.7061.84E−02VasorinILMN_1727466KCNMB41.7005.76E−03Potassium large conductance calcium-activated channel, subfamily M, beta member 4ILMN_2405009NBL11.6952.38E−02Neuroblastoma, suppression of tumorigenicity 1ILMN_1801246IFITM11.6946.27E−04Interferon induced transmembrane protein 1 (9--27)ILMN_2339955**NR4A2** ^**O,\ M**^1.6883.79E−02Nuclear receptor subfamily 4, group A, member 2The fold changes are mean of three independent samples. Superscripts were assigned to drug response genes (D), oxidative stress response genes (O) and metastasis (M) related genes according to gene ontology. These gene symbols are presented in bold style

In the cDNA array data of tBHQ-treated cells and NRF2 siRNA-treated samples, total 18 overlapping genes could be obtained with statistical significance (p \< 0.05) (Table [5](#Tab5){ref-type="table"}). Unexceptionally 17 genes with increased mRNA expression under the tBHQ treatment showed decreased expression by NRF2 siRNA treatment. The metastasis genes whose relationship with NRF2 was reported previously are as follows: *AKR1B10* (Agyeman et al. [@CR3]; Nishinaka et al. [@CR47]), *ALDH3A1* (Agyeman et al. [@CR3]), *TXNRD1* (Sakurai et al. [@CR54]), *AKR1C4* (Ebert et al. [@CR18]), *ALDH1A1* (Duong et al. [@CR16]), *PIR* (Hubner et al. [@CR25]), *GPX2* (Banning et al. [@CR5]), *UGDH* (Loignon et al. [@CR39]), *SRXN1* (Soriano et al. [@CR58]), *ME1* (Thimmulappa et al. [@CR61]), *ABCB6* (Campbell et al. [@CR8]), *EPHX1* (Su et al. [@CR60]), *NQO1* (Agyeman et al. [@CR3]; Loignon et al. [@CR39]; Thimmulappa et al. [@CR61]), and *ABCC3* (Adachi et al. [@CR2]). Interestingly, we identified three new genes including *ALDH3A2*, *ASPH*, and *KISS1* as NRF2-responsive genes in this study. To date no study has been reported the relationship of NRF2 with ALDH3A2, ASPH, and KISS1. KISS1 is a protein with 145 amino acid residues and its role is known as an inhibitor of metastasis (Ji et al. [@CR28]). Overexpression KISS1 inhibits metastatic colony formation in ovarian cancer cell lines (Jiang et al. [@CR29]). However, the role of KISS1 in pancreatic cancers has not yet been elucidated. Previously, a report displayed that *NRF2* deficient mice showed higher number of pulmonary metastasis than wild-type mice (Satoh et al. [@CR55]). ShRNA mediated knockdown of *NRF2* also enhanced cellular plasticity and motility in HepG2 cell (Rachakonda et al. [@CR49]). However, in esophageal squamous cancer cell line NRF2 suppression downregulated the migration and invasion (Shen et al. [@CR56]). Currently, the potential role of NRF2 in regulation of metastasis is under active investigation.Table 5List of statistically significant overlapping genes between two microarray data (tHBQ mediated activation of NRF2 and siRNA mediated depletion of NRF2)SymbolProbe ID agilentProbe ID Ilumina (ILMN\_)Fold change (TBHQ)p ValueFold change (SiRNA)p Value (LPE t test)Gene name**AKR1B10** ^**D,\ O**^A_24_P12934116721484.6948.83E−040.2410.00E+00Aldo--keto reductase family 1, member B10 (aldose reductase)**ALDH3A1** ^**D,\ O**^A_33_P323843317025032.0633.96E−030.4813.84E−06Aldehyde dehydrogenase 3 family, member A1**TXNRD1** ^**D,\ O**^A_33_P335112017170562.0424.10E−030.6312.46E−03Thioredoxin reductase 1**PIR** ^**M**^A_23_P13703517612471.9824.53E−030.5611.83E−02Pirin (iron-binding nuclear protein)**GPX2** ^**D,\ O**^A_23_P303821332051.9714.64E−030.4693.59E−10Glutathione peroxidase 2 (gastrointestinal)**AKR1C4** ^**O**^A_33_P327229116877571.9005.30E−030.5061.81E−04Aldo--keto reductase family 1, member C4 (chlordecone reductase; 3-alpha hydroxysteroid dehydrogenase, type I; dihydrodiol dehydrogenase 4)**UGDH** ^**D,\ M**^A_33_P339660717295631.8565.80E−030.6194.86E−02UDP-glucose 6-dehydrogenase**ALDH1A1** ^**D,\ O,\ M**^A_23_P8309817093481.8266.21E−030.2530.00E+00Aldehyde dehydrogenase 1 family, member A1**SRXN1** ^**O**^A_23_P32011318048221.7796.92E−030.6894.00E−02Sulfiredoxin 1ME1A_23_P819617360421.7717.33E−030.5512.91E−03Malic enzyme 1, NADP(+)-dependent, cytosolic**ABCB6** ^**D**^A_23_P544121939801.5751.27E−020.5095.44E−06ATP-binding cassette, sub-family B (MDR/TAP), member 6**EPHX1** ^**D,\ O**^A_23_P3453717010251.5381.46E−020.5354.13E−05Epoxide hydrolase 1, microsomal (xenobiotic)**HGD** ^**O**^A_23_P25016421982391.5181.58E−020.3935.28E−08Homogentisate 1,2-dioxygenase**NQO1** ^**D,\ O,\ M**^A_23_P20666117202821.4961.72E−020.6591.65E−02NAD(P)H dehydrogenase, quinone 1**ALDH3A2** ^**D,\ O**^A_33_P333661717948251.4631.99E−020.6181.60E−02Aldehyde dehydrogenase 3 family, member A2ASPHA_24_P29524523529341.3753.11E−020.6152.20E−02Aspartate beta-hydroxylase**ABCC3** ^**D,\ O**^A_23_P20750716778141.3304.09E−020.5183.96E−06ATP-binding cassette, sub-family C (CFTR/MRP), member 3**KISS1** ^**M**^A_23_P12489216694040.7714.70E−021.5343.29E−02KiSS-1 metastasis-suppressorThe fold change values are mean of three independent samples. Superscripts were assigned to drug response genes (D), oxidative stress response genes (O) and metastasis (M) related genes according to gene ontology. These gene symbols are presented in bold style
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